A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

NCT00828971 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Infectious Diseases

Interventions

DRUG: Avelox (Moxifloxacin, BAY12-8039)
DRUG: Amoxicilline/clavulanic

Sponsor

Bayer